More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
May 2024 Ophthalmic News Briefs
Author: Market Scope
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-surgical inflammation and pain in key countries in the Middle East and North Africa (MENA). Tabuk is a Saudi company with more than 2,400 employees and a reach of 17 countries across the MENA region. The companies said the deal includes an upfront payment, plus commercialization and sales milestone pa...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
Recommended Products
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.